Valuation: Resverlogix Corp.

Market Cap 26.02M 18.75M 16.19M 15.22M 13.84M 1.79B 26.45M 178M 69.71M 898M 70.39M 68.86M 2.98B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 112M 80.57M 69.59M 65.39M 59.47M 7.7B 114M 766M 300M 3.86B 302M 296M 12.82B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 week+10.53%
Current month+10.53%
1 month+5.00%
3 months+10.53%
6 months+10.53%
Current year+5.00%
1 week 0.1
Extreme 0.095
0.11
1 month 0.09
Extreme 0.09
0.12
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 24/04/2003
Director of Finance/CFO 78 28/10/2009
Chief Tech/Sci/R&D Officer - 14/08/2022
Director TitleAgeSince
Chairman - 03/04/2016
Director/Board Member 56 14/10/2009
Director/Board Member 66 28/09/2010
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Option

Chief Financial Officer

350,000 0.1018%
06/07/26 Option

Chief Financial Officer

-350,000 0.1018%
06/07/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+10.53%-4.55%+5.00% 26.02M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.32%+2.80%+47.03%+185.54% 26.37B
Weighted average by Cap. -1.09%+0.56%+50.23%+164.98%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.5M -4.75M -4.47M -4.06M -526M -7.76M -52.32M -20.46M -263M -20.66M -20.21M -875M -7.77M -5.6M -4.83M -4.54M -4.13M -535M -7.9M -53.23M -20.81M -268M -21.01M -20.56M -891M
Net Debt 81.87M 59M 50.96M 47.88M 43.55M 5.64B 83.22M 561M 219M 2.83B 222M 217M 9.39B 85.79M 61.82M 53.39M 50.17M 45.63M 5.91B 87.2M 588M 230M 2.96B 232M 227M 9.84B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
14/08/26 CA$0.1050 0.00% 7,541
13/08/26 CA$0.1050 +5.00% 65,000
12/08/26 CA$0.1000 0.00% 1,084
11/08/26 CA$0.1000 0.00% 2,950
10/08/26 CA$0.1000 +5.26% 27,000